Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ImmuPharma, which focuses on discovery and development of pharmaceuticals has regained rights to Lupuzor from Cephalon, following its acquisition by Teva Pharmaceutical Industries.
Subscribe to our email newsletter
ImmuPharma and Cephalon had signed an option agreement in 2008,when the ImmuPharma designed and funded Phase IIb study was ongoing.
ImmuPharma was paid $15m by Cephalon before the results of the phase IIb study for the exclusive option to enter into the worldwide license.
Following positive results of the ImmuPharma phase IIb study in early 2009, Cephalon exercised its option by paying a further $30m for an exclusive worldwide license, which was a part of an agreement worth $500m.
Cephalon took over the responsibilities and costs for the development and commercialisation of Lupuzor, after the completion of the license agreement.